{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:22:10Z","timestamp":1785770530453,"version":"3.56.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ico.0b013e31823f8b9c","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T06:41:03Z","timestamp":1329979263000},"page":"907-912","source":"Crossref","is-referenced-by-count":20,"title":["Inhibition of Corneal Neovascularization in Rats by Systemic Administration of Sorafenib"],"prefix":"10.1097","volume":"31","author":[{"given":"Jeong Won","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Hyang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sub","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choun-Ki","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210204","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00417-007-0542-4","article-title":". Inhibition of corneal angiogenesis by ascorbic acid in the rat model.","volume":"245","author":"Peyman","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R2-12-20210204","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0002-9394(68)90821-0","article-title":". Prevention of corneal vascularization.","volume":"66","author":"Ey","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"R3-12-20210204","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bjo.2006.107417","article-title":". Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier.","volume":"91","author":"Ambati","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R4-12-20210204","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors.","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R5-12-20210204","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","article-title":". Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.","volume":"269","author":"Waltenberger","year":"1994","journal-title":"J Biol Chem"},{"key":"R6-12-20210204","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.0.CO;2-V","article-title":"cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation.","volume":"67","author":"DAngelo","year":"1997","journal-title":"J Cell Biochem"},{"key":"R7-12-20210204","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis.","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"R8-12-20210204","doi-asserted-by":"crossref","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","article-title":". Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinaseAkt signal transduction pathway. Requirement for Flk-1KDR activation.","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"key":"R9-12-20210204","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.onc.1201380","article-title":". p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.","volume":"15","author":"Rousseau","year":"1997","journal-title":"Oncogene"},{"key":"R10-12-20210204","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/sj.onc.1202527","article-title":"VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells.","volume":"18","author":"Takahashi","year":"1999","journal-title":"Oncogene"},{"key":"R11-12-20210204","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":". Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell Signal"},{"key":"R12-12-20210204","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0165-6147(02)02109-0","article-title":"Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.","volume":"23","author":"Bikfalvi","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"R13-12-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrd819","article-title":"Angiogenesis modulation in cancer research: novel clinical approaches.","volume":"1","author":"Cristofanilli","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"R14-12-20210204","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm0603-685","article-title":"Molecular regulation of vessel maturation.","volume":"9","author":"Jain","year":"2003","journal-title":"Nat Med"},{"key":"R15-12-20210204","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":". Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest"},{"key":"R16-12-20210204","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":". Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"R18-12-20210204","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":". BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAFMEKERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R19-12-20210204","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bjo.2008.149187","article-title":". Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.","volume":"93","author":"Chung","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R20-12-20210204","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0025-6196(11)60847-1","article-title":". Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.","volume":"83","author":"Diago","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R21-12-20210204","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1016\/j.biomaterials.2009.07.024","article-title":". Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.","volume":"30","author":"Oh","year":"2009","journal-title":"Biomaterials"},{"key":"R22-12-20210204","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":". Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAFMEKERK pathway in tumor cells and tyrosine kinases VEGFRPDGFR in tumor vasculature.","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"R23-12-20210204","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":". Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R24-12-20210204","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":". Sorafenib blocks the RAFMEKERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLCPRF5.","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"R25-12-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":". Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R26-12-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":". Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R27-12-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-12-20210204","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":". Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.","volume":"10","author":"Rini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R29-12-20210204","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1167\/iovs.07-1314","article-title":". Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.","volume":"49","author":"Hos","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-12-20210204","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":". Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R31-12-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":". Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R32-12-20210204","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":". Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201208000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:32:22Z","timestamp":1785767542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201208000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31823f8b9c","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}